Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $43.40.

A number of equities analysts recently issued reports on ELVN shares. HC Wainwright boosted their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Mizuho lifted their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 10,000 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $1,508,580. The trade was a 16.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the completion of the transaction, the insider owned 740,188 shares in the company, valued at $21,495,059.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 16,230 shares of company stock worth $473,201 in the last 90 days. 25.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after purchasing an additional 1,693 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after buying an additional 80,506 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Enliven Therapeutics during the 1st quarter worth $578,000. Legal & General Group Plc increased its stake in shares of Enliven Therapeutics by 52.2% during the second quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after buying an additional 11,058 shares during the period. Finally, Quantbot Technologies LP increased its stake in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $41.20 on Thursday. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $48.53. The firm has a 50-day simple moving average of $36.81 and a two-hundred day simple moving average of $27.20. The company has a market cap of $2.51 billion, a P/E ratio of -22.15 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, equities research analysts expect that Enliven Therapeutics will post -1.7 EPS for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.